Natdecita 50mg Injection

Brand Name: Natdecita

Molecule: Decitabine

Strength: 50 mg

Quantity: Single dose Vial

Form: Injection

Packaging Type: Vial

Manufacturer/Marketed By: Natco Pharma

Country of Origin: India

Description

Natdecita 50 mg Injection contains Decitabine, a hypomethylating antineoplastic agent used in the treatment of myelodysplastic syndromes (MDS) and related bone marrow disorders. It helps restore normal gene function in abnormal cells, improves blood cell production, and slows disease progression. Natdecita is administered intravenously under strict medical supervision.

Benefits

Improves production of healthy blood cells
Reduces dependence on blood transfusions
Slows progression of myelodysplastic syndromes
Helps restore normal gene function in bone marrow cells
Proven treatment option for high-risk MDS patients

Indications and Usage

atdecita 50 mg Injection is indicated for the treatment of:

Myelodysplastic Syndromes (MDS)
- Refractory anemia
- Refractory anemia with ringed sideroblasts
- Refractory anemia with excess blasts
- Refractory anemia with excess blasts in transformation
Chronic Myelomonocytic Leukemia (CMML)
Patients classified as Intermediate-2 or High-Risk (IPSS)
De novo or secondary MDS, previously treated or untreated

Treatment must be initiated and supervised by an oncologist or hematologist.

How it Works

Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation. This restores normal control of cell growth and differentiation in abnormal bone marrow cells and induces cell death in rapidly dividing cancer cells.

Dosage & Administration

Natdecita 50 mg Injection is administered intravenously by trained healthcare professionals only.

Recommended regimens:

Regimen 1

15 mg/m² IV infusion over 3 hours
Every 8 hours for 3 days
Repeated every 6 weeks

Regimen 2

20 mg/m² IV infusion over 1 hour
Once daily for 5 days
Repeated every 4 weeks
A minimum of 4 treatment cycles is recommended
Dose adjustments may be required based on blood count recovery
Regular monitoring of CBC, platelets, liver and kidney function is mandatory

Side Effects

Common side effects:

Neutropenia
Thrombocytopenia
Anemia
Fatigue
Fever
Nausea
Diarrhea or constipation
Cough
Hyperglycemia

Serious side effects:

Severe infections
Febrile neutropenia
Severe bleeding
Liver function abnormalities
Pulmonary edema
Cardiac rhythm disturbances
Intracranial hemorrhage

Warning and Precaution

Causes severe neutropenia and thrombocytopenia
High risk of infections – early use of antibiotics or growth factors may be required
Not recommended during pregnancy – may cause fetal harm
Women should avoid pregnancy during treatment and for 1 month after
Men should avoid fathering a child during treatment and for 2 months after
Use caution in patients with liver or kidney impairment
Not to be used in uncontrolled infections
Cytotoxic drug – proper handling and disposal required

Patient Guidance

Natdecita 50 mg Injection is a prescription-only oncology medicine and must be administered in a hospital or oncology center by trained healthcare professionals. Treatment decisions should be made by a qualified oncologist or hematologist.